Niacin receptor agonists, compositions containing such compounds and methods of treatment

Details for Australian Patent Application No. 2005309737 (hide)

Owner Merck & Co., Inc.

Inventors Chen, Weichun; Tata, James R.; Frie, Jessica L.; Ding, Fa-Xiang; Colletti, Steven L.; Shen, Hong C.; Imbriglio, Jason E.

Agent Spruson & Ferguson

Pub. Number AU-A-2005309737

PCT Pub. Number WO2006/057922

Priority 60/630,281 23.11.04 US

Filing date 18 November 2005

Wipo publication date 1 June 2006

International Classifications

A61K 31/4439 (2006.01)

C07D 403/02 (2006.01) Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group

Event Publications

31 May 2007 PCT application entered the National Phase

  PCT publication WO2006/057922 Priority application(s): WO2006/057922

28 January 2010 Alteration of Name

  The name of the applicant has been altered to Merck Sharp & Dohme Corp.

14 June 2012 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(d). Examination has been requested or an examination report has issued for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2005309747-2-methylene-18,19-dinor-1alpha-hydrox y-homopregnacalciferol and its uses

2005309733-Methods and compositions using immunomodulatory compounds for treatment and management of central nervous system injury